Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | More
 
or
Watchlist | Portfolio
Site News
Contact
Market:

Envveno Medical Corp (NVNO)

Envveno Medical Corp (NVNO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
enVVeno Medical Posts Company Highlights and Materials from 2023 VEITH Symposium ACCESSWIRE - Thu Dec 14, 2023

- Interviews with patients from the VenoValve® pivotal study

NVNO : 5.05 (-0.20%)
enVVeno Medical Presents Positive Preliminary Device Related Material Adverse Event (MAE) Data from the VenoValve Pivotal Trial at the 50th Annual VEITH Symposium ACCESSWIRE - Thu Nov 16, 2023

IRVINE, CA / ACCESSWIRE / November 16, 2023 / enVVeno Medical Corporation (Nasdaq:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous disease, today...

NVNO : 5.05 (-0.20%)
enVVeno Medical Reports Third Quarter 2023 Financial Results and Provides Corporate Update ACCESSWIRE - Thu Oct 26, 2023

- $51.4 million cash on hand sufficient to fund current operations, including multiple value driving milestones, through the end of 2025

NVNO : 5.05 (-0.20%)
JTC Team Announces Presenting Company Line Up for the Virtual Investor “Ask the CEO” Conference Being Held October 24-25, 2023 ACCESSWIRE - Wed Oct 18, 2023

- Live video webcast interactive Q&A with participating companies -

EVFM : 0.0120 (-7.69%)
GRI : 0.4100 (-4.43%)
MBRX : 5.02 (-2.52%)
XBIO : 4.27 (+9.49%)
AREC : 1.4000 (-7.89%)
CNSP : 0.2211 (+2.60%)
NVNO : 5.05 (-0.20%)
PALI : 7.74 (+6.17%)
enVVeno Medical to Participate at the Virtual Investor Ask the CEO Conference ACCESSWIRE - Thu Oct 12, 2023

Live moderated webcast with Robert Berman, Chief Executive Officer of enVVeno Medical on Wednesday, October 25th at 12:00 PM ET

NVNO : 5.05 (-0.20%)
enVVeno Medical Achieves Full Enrollment for VenoValve U.S. Pivotal Trial ACCESSWIRE - Fri Oct 6, 2023

- 18 VenoValve patients enrolled over the final two months of the study

NVNO : 5.05 (-0.20%)
enVVeno Medical Announces New Expedited Development Plan for the enVVe(R) Transcatheter Based Replacement Venous Valve ACCESSWIRE - Fri Oct 6, 2023

- enVVe development cycle to be reduced by 6 months

NVNO : 5.05 (-0.20%)
enVVeno Medical Announces Private Placement of $28 Million ACCESSWIRE - Fri Oct 6, 2023

Up to an additional $34 million of capital may become available from milestone-driven warrants in Q2, 2024 upon the release of initial topline efficacy data from the VenoValve pivotal trial

NVNO : 5.05 (-0.20%)
enVVeno Medical Announces the Issuance of a New Unique Category III CPT Code Covering the Insertion of a Bioprosthetic Valve into the Femoral Vein AccessWire - Fri Jul 8, 2022

IRVINE, CA / ACCESSWIRE / July 8, 2022 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous disease, today announced...

NVNO : 5.05 (-0.20%)
enVVeno Medical Reports First Quarter 2022 Financial Results and Provides Corporate Update AccessWire - Mon May 2, 2022

Our newswire features a comprehensive, flat-fee Press Release service. Generate quality engagement with real-time analytics to improve visibility and expand your influence.

NVNO : 5.05 (-0.20%)

Barchart Exclusives

5 Stocks to Buy on Surging AI Data Center Demand Barchart - 1 hour ago
Financial services giant Goldman Sachs remains bullish on AI data center demand. Here are five stocks they like to play the investing megatrend. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot